“…It may be that the component of the incorporation mechanism which is inhibited by benzimidazole derivatives is not a purine or purine nucleoside. If we take into account the general principles that have been evolved as a result of studies ofantimetabolites (Woolley, 1952 b;Kodicek 1949) we can deduce that the active component must bear a structural relationship to benzimidazole and that positions 4, 5 and 6 are important in determining its activity. Position 1 is clearly important also since substitution with a-ribofuranosyl, glucopyranosyl or dihydroxypropyl in that position abolishes, whereas substitution with allyl increases, the inhibitory activity of 5:6-dimethylbenzimidazole.…”